Adamas Pharmaceuticals Company Profile (NASDAQ:ADMS)

About Adamas Pharmaceuticals (NASDAQ:ADMS)

Adamas Pharmaceuticals logoAdamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ADMS
  • CUSIP: N/A
  • Web:
  • Market Cap: $408.28 million
  • Outstanding Shares: 22,359,000
Average Prices:
  • 50 Day Moving Avg: $17.40
  • 200 Day Moving Avg: $16.84
  • 52 Week Range: $12.10 - $19.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -14.67
  • P/E Growth: -0.06
Sales & Book Value:
  • Annual Revenue: $397,000.00
  • Price / Sales: 1,008.13
  • Book Value: $5.36 per share
  • Price / Book: 3.34
  • EBIDTA: ($64,670,000.00)
  • Net Margins: -10,499.65%
  • Return on Equity: -45.19%
  • Return on Assets: -41.73%
  • Current Ratio: 13.95%
  • Quick Ratio: 13.95%
  • Average Volume: 167,790 shs.
  • Beta: 0.84
  • Short Ratio: 16.03
Frequently Asked Questions for Adamas Pharmaceuticals (NASDAQ:ADMS)

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) announced its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.72) EPS for the quarter, meeting the consensus estimate of ($0.72). Adamas Pharmaceuticals had a negative return on equity of 45.19% and a negative net margin of 10,499.65%. During the same quarter in the prior year, the firm earned ($0.65) EPS. View Adamas Pharmaceuticals' Earnings History.

When will Adamas Pharmaceuticals make its next earnings announcement?

Adamas Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Adamas Pharmaceuticals.

Where is Adamas Pharmaceuticals' stock going? Where will Adamas Pharmaceuticals' stock price be in 2017?

4 brokers have issued 12 month target prices for Adamas Pharmaceuticals' stock. Their predictions range from $26.00 to $45.00. On average, they anticipate Adamas Pharmaceuticals' stock price to reach $35.50 in the next twelve months. View Analyst Ratings for Adamas Pharmaceuticals.

What are analysts saying about Adamas Pharmaceuticals stock?

Here are some recent quotes from research analysts about Adamas Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. " (7/11/2017)
  • 2. Mizuho analysts commented, "We updated our model post-1Q:17 and the recent royalty financing." (6/6/2017)

Who are some of Adamas Pharmaceuticals' key competitors?

Who are Adamas Pharmaceuticals' key executives?

Adamas Pharmaceuticals' management team includes the folowing people:

  • Gregory T. Went Ph.D., Chairman of the Board, Chief Executive Officer
  • Alfred G. Merriweather, Chief Financial Officer
  • Richard A. King, Chief Operating Officer
  • Leonie McConville, Senior Vice President - Human Resources
  • Natalie L. McClure Ph.D., Senior Vice President - Product Development
  • Jennifer J. Rhodes, Chief Compliance Officer, General Counsel, Corporate Secretary
  • Martin Forrest, Vice President, Corporate Communications and Investor Relations
  • Rajiv Patni M.D., Chief Medical Officer
  • David L. Mahoney, Lead Independent Director
  • Michael F. Bigham, Director

Who owns Adamas Pharmaceuticals stock?

Adamas Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Cheyne Capital Management UK LLP (0.49%), Private Asset Management Inc. (0.15%) and Russell Investments Group Ltd. (0.04%). Company insiders that own Adamas Pharmaceuticals stock include Great Point Partners Llc, Gregory T Went, Ivan M Lieberburg, Ix Lp Mdv, Jennifer J Rhodes, Natalie Mcclure, Rajiv Patni, William J Dawson and William W Ericson. View Institutional Ownership Trends for Adamas Pharmaceuticals.

Who sold Adamas Pharmaceuticals stock? Who is selling Adamas Pharmaceuticals stock?

Adamas Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd. and Cheyne Capital Management UK LLP. Company insiders that have sold Adamas Pharmaceuticals stock in the last year include Great Point Partners Llc, Gregory T Went, Jennifer J Rhodes, Rajiv Patni and William J Dawson. View Insider Buying and Selling for Adamas Pharmaceuticals.

How do I buy Adamas Pharmaceuticals stock?

Shares of Adamas Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adamas Pharmaceuticals' stock price today?

One share of Adamas Pharmaceuticals stock can currently be purchased for approximately $17.90.

MarketBeat Community Rating for Adamas Pharmaceuticals (NASDAQ ADMS)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  136 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  208
MarketBeat's community ratings are surveys of what our community members think about Adamas Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Adamas Pharmaceuticals (NASDAQ:ADMS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $35.50 (98.32% upside)

Analysts' Ratings History for Adamas Pharmaceuticals (NASDAQ:ADMS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/6/2017MizuhoReiterated RatingBuy$26.00LowView Rating Details
5/28/2017Cowen and CompanyReiterated RatingOutperform$45.00LowView Rating Details
5/12/2017Noble FinancialReiterated RatingBuyLowView Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
7/25/2016Credit Suisse GroupReiterated RatingBuy$21.00N/AView Rating Details
7/20/2016Needham & Company LLCReiterated RatingBuy$38.00N/AView Rating Details
6/14/2016Piper Jaffray CompaniesReiterated RatingOverweight$44.00N/AView Rating Details
1/26/2016AegisReiterated RatingBuyN/AView Rating Details
9/11/2015William BlairReiterated RatingOutperform$35.00N/AView Rating Details
(Data available from 7/27/2015 forward)


Earnings History for Adamas Pharmaceuticals (NASDAQ:ADMS)
Earnings by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)
Earnings History by Quarter for Adamas Pharmaceuticals (NASDAQ ADMS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017($0.81)N/AView Earnings Details
5/9/2017Q1 2017($0.72)($0.72)$0.11 millionViewListenView Earnings Details
2/28/2017Q4($0.80)($0.68)$0.17 million$0.04 millionViewN/AView Earnings Details
11/3/2016Q3 2016($0.83)($0.66)$0.26 million$0.14 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.71)($0.78)$0.18 million$0.22 millionViewN/AView Earnings Details
5/10/2016Q1($0.76)($0.65)$0.18 millionViewN/AView Earnings Details
2/23/2016Q4($0.81)($0.58)$0.10 million$0.52 millionViewN/AView Earnings Details
11/12/2015Q3($0.79)($0.81)$0.10 million$0.77 millionViewN/AView Earnings Details
8/11/2015Q215($0.67)($0.78)$0.10 million$0.40 millionViewN/AView Earnings Details
5/13/2015Q414($0.74)($0.69)$0.10 million$0.23 millionViewN/AView Earnings Details
3/3/2015Q4 2014$0.64$0.50$30.18 million$30.30 millionViewN/AView Earnings Details
11/4/2014Q314($0.44)($0.57)$0.18 million$0.22 millionViewN/AView Earnings Details
8/7/2014Q214$2.07$0.88$18.75 million$25.15 millionViewN/AView Earnings Details
5/13/2014Q114($0.09)($0.67)$30.60 million$0.18 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Adamas Pharmaceuticals (NASDAQ:ADMS)
2017 EPS Consensus Estimate: ($3.48)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.64)($0.64)($0.64)
Q2 20171($0.84)($0.84)($0.84)
Q3 20171($0.96)($0.96)($0.96)
Q4 20171($1.04)($1.04)($1.04)
(Data provided by Zacks Investment Research)


Dividend History for Adamas Pharmaceuticals (NASDAQ:ADMS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Adamas Pharmaceuticals (NASDAQ:ADMS)
Insider Ownership Percentage: 29.00%
Institutional Ownership Percentage: 71.43%
Insider Trades by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)
Institutional Ownership by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)
Insider Trades by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/21/2017Great Point Partners LlcMajor ShareholderSell380,000$17.08$6,490,400.00View SEC Filing  
6/21/2017Jennifer J. RhodesInsiderSell1,041$17.53$18,248.73View SEC Filing  
6/19/2017Great Point Partners LlcMajor ShareholderSell350,000$17.05$5,967,500.00View SEC Filing  
3/21/2017Gregory T WentCEOSell2,807$17.03$47,803.21View SEC Filing  
3/21/2017Rajiv PatniInsiderSell733$17.04$12,490.32View SEC Filing  
3/21/2017William J DawsonCFOSell716$17.02$12,186.32View SEC Filing  
9/16/2016Ix Lp MdvMajor ShareholderBuy62,977$16.48$1,037,860.96View SEC Filing  
9/13/2016Ix Lp MdvMajor ShareholderBuy84,376$15.58$1,314,578.08View SEC Filing  
9/7/2016William W EricsonDirectorBuy60,846$15.68$954,065.28View SEC Filing  
9/6/2016Ix Lp MdvMajor ShareholderBuy50,919$14.79$753,092.01View SEC Filing  
9/6/2016William W EricsonDirectorBuy7,200$15.00$108,000.00View SEC Filing  
9/2/2016William W EricsonDirectorBuy43,719$14.75$644,855.25View SEC Filing  
4/18/2016Natalie McclureSVPSell36,000$18.50$666,000.00View SEC Filing  
12/7/2015Ivan M LieberburgDirectorSell3,000$16.23$48,690.00View SEC Filing  
10/5/2015Ivan M LieberburgDirectorSell3,000$16.75$50,250.00View SEC Filing  
9/8/2015Ivan M LieberburgDirectorSell3,000$19.13$57,390.00View SEC Filing  
7/6/2015Ivan M LieberburgDirectorSell3,000$25.91$77,730.00View SEC Filing  
6/5/2015Natalie McclureSVPSell2,000$18.95$37,900.00View SEC Filing  
5/18/2015Ix Lp MdvMajor ShareholderSell1,643$18.04$29,639.72View SEC Filing  
5/15/2015Richard H BoothDirectorSell1,000$17.85$17,850.00View SEC Filing  
5/14/2015Gregory T WentCEOSell2,728$18.00$49,104.00View SEC Filing  
4/23/2015Gregory T WentCEOSell3,300$18.00$59,400.00View SEC Filing  
4/21/2015Gregory T WentCEOSell962$18.01$17,325.62View SEC Filing  
4/20/2015Gregory T WentCEOSell2,610$18.00$46,980.00View SEC Filing  
4/15/2015Richard H BoothDirectorSell1,000$17.72$17,720.00View SEC Filing  
4/14/2015Gregory T WentCEOSell14,757$7.15$105,512.55View SEC Filing  
4/10/2015William W EricsonDirectorSell37,078$18.56$688,167.68View SEC Filing  
4/6/2015Ivan M LieberburgDirectorSell3,000$17.44$52,320.00View SEC Filing  
4/6/2015Natalie McclureSVPSell2,000$17.44$34,880.00View SEC Filing  
3/19/2015Gregory T WentCEOSell23,088$18.00$415,584.00View SEC Filing  
3/18/2015Ix Lp MdvMajor ShareholderSell11,723$18.02$211,248.46View SEC Filing  
3/16/2015Richard H BoothDirectorSell1,000$17.36$17,360.00View SEC Filing  
3/13/2015Aeris Capital Equity InvestmenMajor ShareholderSell350,000$17.23$6,030,500.00View SEC Filing  
2/17/2015Richard H BoothDirectorSell1,000$16.54$16,540.00View SEC Filing  
2/5/2015Natalie McclureSVPSell2,000$16.87$33,740.00View SEC Filing  
2/2/2015Ivan M LieberburgDirectorSell3,000$16.77$50,310.00View SEC Filing  
1/5/2015Ivan M LieberburgDirectorSell3,000$17.59$52,770.00View SEC Filing  
1/5/2015Natalie McclureSVPSell2,000$17.59$35,180.00View SEC Filing  
12/24/2014Richard H BoothDirectorSell2,000$17.51$35,020.00View SEC Filing  
12/3/2014Aeris Capital Equity InvestmenMajor ShareholderSell111,625$14.51$1,619,678.75View SEC Filing  
12/1/2014Aeris Capital Equity InvestmenMajor ShareholderSell13,615$14.54$197,962.10View SEC Filing  
12/1/2014Natalie McclureSVPSell20,000$14.50$290,000.00View SEC Filing  
11/26/2014Aeris Capital Equity InvestmenMajor ShareholderSell12,500$14.77$184,625.00View SEC Filing  
11/25/2014Aeris Capital Equity InvestmenMajor ShareholderSell10,000$14.85$148,500.00View SEC Filing  
4/15/2014William W EricsonDirectorBuy300,000$16.00$4,800,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Adamas Pharmaceuticals (NASDAQ:ADMS)
Latest Headlines for Adamas Pharmaceuticals (NASDAQ:ADMS)
DateHeadline logoAdamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Scheduled to Post Earnings on Wednesday - July 26 at 7:10 AM logoETFs with exposure to Adamas Pharmaceuticals, Inc. : July 24, 2017 - July 24 at 6:51 PM logoAdamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Downgraded to Sell at BidaskClub - July 23 at 8:52 PM logoAdamas Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ADMS) : July 14, 2017 - July 14 at 10:19 PM logoETFs with exposure to Adamas Pharmaceuticals, Inc. : July 14, 2017 - July 14 at 5:18 PM logoQ3 Biotech Catalyst Watch: Key PDUFAs (Part 3) - July 13 at 4:07 PM logoAdamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ADMS-US : July 13, 2017 - July 13 at 4:07 PM logoAdamas Pharmaceuticals, Inc. (ADMS) Upgraded to "Hold" by Zacks Investment Research - July 11 at 11:26 PM logoAdamas Reports Inducement Grant to New Chief Financial Officer - July 10 at 8:33 PM logoAdamas Pharmaceuticals, Inc. (ADMS) Given Consensus Recommendation of "Buy" by Brokerages - July 3 at 8:44 PM logo-$0.85 EPS Expected for Adamas Pharmaceuticals, Inc. (ADMS) This Quarter - June 27 at 2:20 PM logoAdamas Pharmaceuticals, Inc. (ADMS) Insider Jennifer J. Rhodes Sells 1,041 Shares - June 22 at 8:17 PM logoAdamas Pharmaceuticals (ADMS) Presents At JMP Securities Life Sciences Conference 2017 - Slideshow - June 22 at 12:52 PM logoAdamas Pharmaceuticals, Inc. (ADMS) Major Shareholder Sells $5,967,500.00 in Stock - June 21 at 10:27 PM logoAdamas Pharmaceuticals, Inc. (ADMS) Major Shareholder Sells $6,490,400.00 in Stock - June 21 at 10:27 PM logoAdamas Announces Publication of ADS-5102 Phase 3 EASE LID Clinical Trial in JAMA Neurology - June 13 at 5:40 AM logoAdamas Pharma (ADMS) Announces Expanded Analysis from the ADS-5102 Open-Label Study - June 9 at 3:25 PM logoAdamas Provides Positive Long-term Data on Parkinson's Drug - June 9 at 3:25 PM logoAdamas Presents Expanded Analysis from the ADS-5102 Open-Label Study Showing Tolerability and Durability out to 88 Weeks - June 8 at 8:26 PM logoAdamas Pharmaceuticals (ADMS) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow - June 8 at 1:27 AM logoAdamas Pharmaceuticals Inc (ADMS) Receives Average Rating of "Buy" from Brokerages - June 6 at 8:33 PM logoAdamas Pharmaceuticals Inc (ADMS) Earns "Buy" Rating from Mizuho - June 6 at 1:40 PM logoAdamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ADMS-US : June 5, 2017 - June 5 at 1:39 PM logoAdamas to Present at Two Upcoming Investor Conferences - June 1 at 3:28 PM logoAdamas Pharmaceuticals Inc (ADMS) Expected to Announce Earnings of -$0.85 Per Share - June 1 at 12:30 PM logoCowen and Company Reaffirms "Outperform" Rating for Adamas Pharmaceuticals Inc (ADMS) - May 28 at 10:54 AM logoAdamas Epilepsy Drug Shows Positive Result in Phase Ia Study - May 23 at 3:22 PM logoAdamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy - May 22 at 3:21 PM logoAdamas Pharmaceuticals Inc (ADMS) Stock Rating Reaffirmed by Noble Financial - May 13 at 11:32 AM logoAdamas Pharmaceuticals Inc (ADMS) Lowered to "Sell" at Zacks Investment Research - May 12 at 8:56 PM logoAdamas Pharmaceuticals Inc (ADMS) Receives Average Recommendation of "Buy" from Analysts - May 12 at 6:42 PM logoAdamas Pharmaceuticals Inc to Post Q2 2017 Earnings of ($0.84) Per Share, William Blair Forecasts (ADMS) - May 12 at 10:42 AM logoAdamas Pharmaceuticals' (ADMS) CEO Gregory Went on Q1 2017 Results - Earnings Call Transcript - May 11 at 3:35 PM logoAdamas Signs $100 Million Royalty-Backed Note Agreement with HealthCare Royalty Partners - May 11 at 3:35 PM logoAdamas Signs $100 Million Royalty-Backed Note Agreement with HealthCare Royalty Partners - May 11 at 3:35 PM logoEdited Transcript of ADMS earnings conference call or presentation 9-May-17 8:30pm GMT - May 11 at 3:35 PM logo[$$] Adamas Receives $100 Million Royalty-Backed Financing From HealthCare Royalty Partners - May 11 at 3:35 PM logoAdamas Pharmaceuticals Inc (ADMS) Releases Earnings Results, Hits Expectations - May 10 at 9:14 PM logoAdamas Pharmaceuticals Inc (ADMS) Expected to Post Quarterly Sales of $580,000.00 - May 10 at 11:34 AM logoAdamas Reports Recent Achievements and First Quarter 2017 Financial Results - May 9 at 8:21 PM logoAdamas reports 1Q loss - May 9 at 6:45 PM logoInvestor Network: Adamas Pharmaceuticals, Inc. to Host Earnings Call - May 9 at 3:20 PM logo Analysts Expect Adamas Pharmaceuticals Inc (ADMS) to Announce -$0.72 EPS - May 8 at 10:50 AM logoAdamas Pharmaceuticals Inc (ADMS) Scheduled to Post Earnings on Tuesday - May 7 at 7:02 AM logoAdamas Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ADMS) : May 5, 2017 - May 5 at 8:21 PM logoAdamas Reports Inducement Grant to New Chief Operating Officer - May 5 at 8:21 PM logoAdamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ADMS-US : May 4, 2017 - May 4 at 3:21 PM logoAdamas to Announce First Quarter 2017 Financial Results and Host Conference Call on May 9, 2017 - May 3 at 6:59 AM logoAdamas Pharmaceuticals (ADMS) Getting Positive News Coverage, Study Finds - May 2 at 9:18 AM logoAdamas Appoints Richard A. King as Chief Operating Officer to Lead Commercialization of ADS-5102 - April 27 at 8:39 PM



Adamas Pharmaceuticals (ADMS) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by Staff